Inducible CYP2J2 and Its Product 11,12-EET Promotes Bacterial Phagocytosis: A Role for CYP2J2 Deficiency in the Pathogenesis of Crohn's Disease?

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Bystrom, Jonas ^a   Thomson, Scott J ^b   Johansson, Jörgen ^c   Edin, Matthew L ^d   Zeldin, Darryl C ^d   Gilroy, Derek W ^e   Smith, Andrew M ^e   Bishop Bailey, David ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; CD11B ANTIGEN; CD68 ANTIGEN; CYTOCHROME P450 2J2; HEPOXILIN A; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROADIFEN;

ARTICLE; BACTERIAL CLEARANCE; CELL TRANSFORMATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; ENZYME INDUCTION; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LISTERIA MONOCYTOGENES; MACROPHAGE; MONOCYTE; NONHUMAN; PHAGOCYTOSIS;

8,11,14-EICOSATRIENOIC ACID; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE; CROHN DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ESCHERICHIA COLI; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MONOCYTES; PHAGOCYTOSIS;

EID: 84884127711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075107     Document Type: Article

References (41)

1. Mantovani A, Sica A, Locati M, (2005) Macrophage polarization comes of age. Immunity 23: 344-346.
2. Bishop-Bailey D, Wray J, (2003) Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 71: 1-22.
3. Zeldin DC, (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062.
4. Campbell WB, Fleming I, (2010) Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 459: 881-895.
5. Capdevila JH, Falck JR, Harris RC, (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163-181.
6. Spiecker M, Liao JK, (2005) Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433: 413-420.
7. Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, et al. (2011) Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 6: e26591.
8. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC, (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468.
9. Werner K, Schaefer WR, Schweer H, Deppert WR, Karck U, et al. (2002) Characterization and identification of cytochrome P450 metabolites of arachidonic acid released by human peritoneal macrophages obtained from the pouch of Douglas. Prostaglandins Leukot Essent Fatty Acids 67: 397-404.
10. Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, et al. (2009) The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PLoS One 4: e7421.
11. Nakayama K, Nitto T, Inoue T, Node K, (2008) Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci 83: 339-345.
12. Kundu S, Roome T, Bhattacharjee A, Carnevale KA, Yakubenko VP, et al. (2013) Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. J Lipid Res 54: 436-447.
13. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, et al. (2011) Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 25: 703-713.
14. Zhang W, Yang AL, Liao J, Li H, Dong H, et al. (2012) Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice. Dig Dis Sci 57: 2580-2591.
15. Zhang W, Liao J, Li H, Dong H, Bai H, et al. (2012) Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency. Mol Carcinog 52: 726-738.
16. Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, et al. (2009) Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 206: 1883-1897.
17. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, et al. (1995) Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108: 1396-1404.
18. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, et al. (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 16: 2777-2780.
19. Bain B, Pshyk K, (1972) Enhanced reactivity in mixed leukocyte cultures after separation of mononuclear cells on Ficoll-Hypaque. Transplant Proc 4: 163-164.
20. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA, (1998) Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 18: 1655-1661.
21. Harvey RF, Bradshaw JM, (1980) A simple index of Crohn's-disease activity. Lancet 1: 514.
22. Schroeder KW, Tremaine WJ, Ilstrup DM, (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629.
23. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, et al. (2006) Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367: 668-678.
24. Bishop-Bailey D, Hla T, Warner TD, (2002) Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res 91: 210-217.
25. Glaser P, Frangeul L, Buchrieser C, Rusniok C, Amend A, et al. (2001) Comparative genomics of Listeria species. Science 294: 849-852.
26. Mandin P, Fsihi H, Dussurget O, Vergassola M, Milohanic E, et al. (2005) VirR, a response regulator critical for Listeria monocytogenes virulence. Mol Microbiol 57: 1367-1380.
27. Lafite P, Dijols S, Zeldin DC, Dansette PM, Mansuy D, (2007) Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys 464: 155-168.
28. Moore KJ, Andersson LP, Ingalls RR, Monks BG, Li R, et al. (2000) Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol 165: 4272-4280.
29. Drevets DA, Leenen PJ, Campbell PA, (1993) Complement receptor type 3 (CD11b/CD18) involvement is essential for killing of Listeria monocytogenes by mouse macrophages. J Immunol 151: 5431-5439.
30. Ma J, Ramachandran S, Fiedorek FT Jr, Zeldin DC, (1998) Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4. Genomics 49: 152-155.
31. Herse F, Lamarca B, Hubel CA, Kaartokallio T, Lokki AI, et al. (2012) Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation 126: 2990-2999.
32. Nakayama K, Nitto T, Inoue T, Node K, (2008) Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci 83: 339-345.
33. Thomson SJ, Askari A, Bishop-Bailey D, (2012) Anti-inflammatory effects of epoxyeicosatrienoic acids. Int J Vasc Med 2012: 605101.
34. da Silva RP, Platt N, de Villiers JS, Gordon S, (1996) Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and vacuolar functions. Biochem Soc Trans 24: 220-224.
35. Ehlers MR, (2000) CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect 2: 289-294.
36. Izbeki F, Nagy F, Szepes Z, Kiss I, Lonovics J, et al. (2008) Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Inflamm Bowel Dis 14: 429-431.
37. Williams G, Khan AA, Schweiger F, (2005) Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 16: 289-292.
38. Willson KJ, Jacob A, Shetti MP, Bhatia R, Yee K, et al. (2012) Listeria monocytogenes infection in Crohn's disease treated with adalimumab. Med J Aust 197: 466-467.
39. Vainer B, Nielsen OH, Horn T, (2000) Comparative studies of the colonic in situ expression of intercellular adhesion molecules (ICAM-1,-2, and-3), beta2 integrins (LFA-1, Mac-1, and p150,95), and PECAM-1 in ulcerative colitis and Crohn's disease. Am J Surg Pathol 24: 1115-1124.
40. Askari A, Thomson SJ, Edin ML, Zeldin DC, Bishop-Bailey D (2013) Roles of the epoxygenase CYP2J2 in the endothelium. Prostaglandins Other Lipid Mediat. In press.
41. Baumgart DC, Sandborn WJ, (2012) Crohn's disease. Lancet 380: 1590-1605.